Signaling Pathway
Emirodatamab is a monoclonal antibody designed to target both CD3E and FLT3. This dual-specificity allows for potential applications in modulating immune responses and targeting FLT3-associated malignancies. Emirodatamab's unique ability to bind these two distinct antigens makes it a valuable tool for research in immunotherapy and hematologic cancers.
重要通知：仅供研究使用。我们不向患者销售。
| Discription | Emirodatamab is a monoclonal antibody designed to target both CD3E and FLT3. This dual-specificity allows for potential applications in modulating immune responses and targeting FLT3-associated malignancies. Emirodatamab's unique ability to bind these two distinct antigens makes it a valuable tool for research in immunotherapy and hematologic cancers. |
||
|---|---|---|---|
| Targets |
|
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2
